Psychedelic therapies are moving closer to regulatory approval, but what will it take to translate clinical research into real-world delivery?
In this episode of MAC: Behind the Trials, host Chris Chadwick is joined by Dr. Shoona Vincent, VP of Clinical Science, and Dr. Lucy McLellan, Associate Medical Director at MAC Clinical Research, to explore the regulatory, scientific and operational realities shaping psychedelic drug development.
The conversation covers regulatory expectations from the FDA and EMA, the complexity of running Schedule 1 clinical trials, and the challenge of bridging tightly controlled studies with real-world clinical practice.
With countries preparing for market readiness and late-stage programmes advancing, the focus is shifting from innovation to implementation.
